Adagene Inc. (ADAG): Total Liabilities
$26.36M
As of 2025-12-31
-27.5%
3-year compound annual growth
+6.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.36M | -32.0% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $38.74M | -14.2% | 2026-04-01, Balance as of period end |
| 2023-12-31 | $45.17M | -34.8% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $69.31M | +110.3% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $32.95M | +71.6% | 2023-04-28, Balance as of period end |
| 2020-12-31 | $19.20M | +120.8% | 2022-04-26, Balance as of period end |
| 2019-12-31 | $8.70M | n/a | 2021-04-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Adagene Inc. (ADAG) | 2025-12-31 | $26.36M | -32.0% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $30.24M | -28.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $51.40M | +18.9% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $14.52M | -18.6% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $416.27M | +66.7% |
| Immunome Inc. (IMNM) | 2025-12-31 | $48.84M | -17.3% |
Compare ADAG, BOLT, ACRS, XENE side by side · Screen every company in Pharmaceutical Preparations ↗